Less than 30% of acute myeloid leukemia (AML) patients survive longer than 5 years. The metabolism of leukemic cells supports their production of energy and building blocks for growth and their capacity to resist to external attacks, as therapies. The study aims to identify metabolic activities of leukemic cells that lead to tumor cell death, once they have been switched off. This approach will combine genome and metabolism analysis, in order to identify and test, in the laboratory, personalized therapies. Moreover, the study will capture AML patients’ preferences towards benefits and risks associated with different treatment options as well as their perspective towards this personalized approach. The study results will converge to a new model of personalized medicine in AML, meaning a new model of approaching the patient and taking decisions on his/her therapeutic path, based on his/her specificities, as patient and as human being and on direct patient involvement.